Using TRIM5α as an HIV therapeutic: The alpha gene?

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: As HIV continues to spread worldwide, new therapies which have the potential to treat and cure infected patients need to be developed. The results observed with the "Berlin patient" who received a bone marrow transplant with HIV-resistant hematopoietic stem cells highlight the potential of HIV gene therapy to be used as an alternative treatment. With the discovery of TRIM5α, an HIV inhibitor and species-specific restriction factor, a new molecule can be evaluated as an HIV gene therapeutic. Nonhuman primate TRIM5α orthologs restrict HIV infection, whereas human TRIM5α does not. However, upon genetic modification, variations to human TRIM5α have been made which are capable of potent HIV restriction. Areas covered: This review seeks to cover the discovery and biology of various HIV-restrictive nonhuman primate TRIM5α orthologs, modifications made to human TRIM5α to enable HIV restriction, and the use of these molecules in an HIV gene therapy setting. Expert opinion: Engineered human TRIM5α molecules, demonstrated to be strong inhibitors of HIV infection, have the potential of being used as new HIV therapeutics in human gene therapy clinical trials. By combining TRIM5α with other highly potent anti-HIV molecules, the generation of an HIV-resistant immune system and potential cure for infected patients may be accomplished.

Original languageEnglish (US)
Pages (from-to)1029-1038
Number of pages10
JournalExpert Opinion on Biological Therapy
Volume13
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Gene therapy
Genes
HIV
Molecules
Transplants
Immune system
Therapeutics
Stem cells
Genetic Therapy
Bone
Primates
HIV Infections
Expert Testimony
Berlin
Hematopoietic Stem Cells
Immune System
Bone Marrow
Clinical Trials

Keywords

  • Anti-HIV vector
  • Gene therapy
  • HIV
  • TRIM5α

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Using TRIM5α as an HIV therapeutic : The alpha gene? / Anderson, Joseph S.

In: Expert Opinion on Biological Therapy, Vol. 13, No. 7, 07.2013, p. 1029-1038.

Research output: Contribution to journalArticle

@article{680895e106ba43df90a89158b7b0ac4c,
title = "Using TRIM5α as an HIV therapeutic: The alpha gene?",
abstract = "Introduction: As HIV continues to spread worldwide, new therapies which have the potential to treat and cure infected patients need to be developed. The results observed with the {"}Berlin patient{"} who received a bone marrow transplant with HIV-resistant hematopoietic stem cells highlight the potential of HIV gene therapy to be used as an alternative treatment. With the discovery of TRIM5α, an HIV inhibitor and species-specific restriction factor, a new molecule can be evaluated as an HIV gene therapeutic. Nonhuman primate TRIM5α orthologs restrict HIV infection, whereas human TRIM5α does not. However, upon genetic modification, variations to human TRIM5α have been made which are capable of potent HIV restriction. Areas covered: This review seeks to cover the discovery and biology of various HIV-restrictive nonhuman primate TRIM5α orthologs, modifications made to human TRIM5α to enable HIV restriction, and the use of these molecules in an HIV gene therapy setting. Expert opinion: Engineered human TRIM5α molecules, demonstrated to be strong inhibitors of HIV infection, have the potential of being used as new HIV therapeutics in human gene therapy clinical trials. By combining TRIM5α with other highly potent anti-HIV molecules, the generation of an HIV-resistant immune system and potential cure for infected patients may be accomplished.",
keywords = "Anti-HIV vector, Gene therapy, HIV, TRIM5α",
author = "Anderson, {Joseph S}",
year = "2013",
month = "7",
doi = "10.1517/14712598.2013.779251",
language = "English (US)",
volume = "13",
pages = "1029--1038",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Using TRIM5α as an HIV therapeutic

T2 - The alpha gene?

AU - Anderson, Joseph S

PY - 2013/7

Y1 - 2013/7

N2 - Introduction: As HIV continues to spread worldwide, new therapies which have the potential to treat and cure infected patients need to be developed. The results observed with the "Berlin patient" who received a bone marrow transplant with HIV-resistant hematopoietic stem cells highlight the potential of HIV gene therapy to be used as an alternative treatment. With the discovery of TRIM5α, an HIV inhibitor and species-specific restriction factor, a new molecule can be evaluated as an HIV gene therapeutic. Nonhuman primate TRIM5α orthologs restrict HIV infection, whereas human TRIM5α does not. However, upon genetic modification, variations to human TRIM5α have been made which are capable of potent HIV restriction. Areas covered: This review seeks to cover the discovery and biology of various HIV-restrictive nonhuman primate TRIM5α orthologs, modifications made to human TRIM5α to enable HIV restriction, and the use of these molecules in an HIV gene therapy setting. Expert opinion: Engineered human TRIM5α molecules, demonstrated to be strong inhibitors of HIV infection, have the potential of being used as new HIV therapeutics in human gene therapy clinical trials. By combining TRIM5α with other highly potent anti-HIV molecules, the generation of an HIV-resistant immune system and potential cure for infected patients may be accomplished.

AB - Introduction: As HIV continues to spread worldwide, new therapies which have the potential to treat and cure infected patients need to be developed. The results observed with the "Berlin patient" who received a bone marrow transplant with HIV-resistant hematopoietic stem cells highlight the potential of HIV gene therapy to be used as an alternative treatment. With the discovery of TRIM5α, an HIV inhibitor and species-specific restriction factor, a new molecule can be evaluated as an HIV gene therapeutic. Nonhuman primate TRIM5α orthologs restrict HIV infection, whereas human TRIM5α does not. However, upon genetic modification, variations to human TRIM5α have been made which are capable of potent HIV restriction. Areas covered: This review seeks to cover the discovery and biology of various HIV-restrictive nonhuman primate TRIM5α orthologs, modifications made to human TRIM5α to enable HIV restriction, and the use of these molecules in an HIV gene therapy setting. Expert opinion: Engineered human TRIM5α molecules, demonstrated to be strong inhibitors of HIV infection, have the potential of being used as new HIV therapeutics in human gene therapy clinical trials. By combining TRIM5α with other highly potent anti-HIV molecules, the generation of an HIV-resistant immune system and potential cure for infected patients may be accomplished.

KW - Anti-HIV vector

KW - Gene therapy

KW - HIV

KW - TRIM5α

UR - http://www.scopus.com/inward/record.url?scp=84878907972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878907972&partnerID=8YFLogxK

U2 - 10.1517/14712598.2013.779251

DO - 10.1517/14712598.2013.779251

M3 - Article

C2 - 23480791

AN - SCOPUS:84878907972

VL - 13

SP - 1029

EP - 1038

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 7

ER -